Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Letters in Drug Design and Discovery is Scopus-indexed (Q3, CiteScore 2.2), WoS SCIE. Published by KeAi Communications Co..
Checked against the index lists dated .
ISSN 1570-1808Verify ISSN ↗1875-628XVerify ISSN ↗
Publisher: KeAi Communications Co.
Cost to publish: About US$2,300 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmaceutical Science | 115 / 191 | 40th | Q3 |
| Drug Discovery | 127 / 161 | 21st | Q4 |
| Molecular Medicine | 155 / 179 | 13th | Q4 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2005–present, best quartile Q3, CiteScore 2.2.
Letters in Drug Design and Discovery is Q3 in Pharmaceutical Science (rank 115 of 191), Q4 in Drug Discovery (rank 127 of 161) and Q4 in Molecular Medicine (rank 155 of 179), by CiteScore 2025.
Letters in Drug Design and Discovery is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 2.2, which places it in quartile Q3 at the 40th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.301, quartile Q3, with an H-index of 41.
The publisher lists an article processing charge of about US$2,300 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Letters in Drug Design and Discovery is published by KeAi Communications Co. Its print ISSN is 1570-1808 and its online ISSN is 1875-628X.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Letters in Drug Design and Discovery has an h-index of 40 and a 2-year mean of 1.19 citations per paper (OpenAlex). Its Scopus CiteScore is 2.2, quartile Q3. On 2-year citations it ranks #105 of 177 Scopus journals in Pharmaceutical Science.
Letters in Drug Design and Discovery published 272 papers in 2025. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 87 research articles (2026), authors are most often from China (67.2%), India (14.6%) and Pakistan (5%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 3 retracted papers are recorded (0.9 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.